Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole Efficacy and Safety in Acute Psychosis Treatment
NCT00304655Phase 4Completed
- Sponsor
- Otsuka Holdings
- Start
- Jul 2004
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aripiprazole in schizophrenia, schizoaffective disorder and schizophreniform disorder, sponsored by Otsuka Holdings. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 52 weeks. Started Jul 2004; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT00304655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304655.